Sipholenol A, a Marine-Derived Sipholane Triterpene, Potently Reverses P-glycoprotein-mediated Multidrug Mesistance in Cancer Cells

Zhi Shi,Sandeep Jain,In‐Wha Kim,Xingxiang Peng,Ioana Abraham,Liwu Fu,Diaa T. A. Youssef,Khalid A. El Sayed,Suresh V. Ambudkar,Zhe‐Sheng Chen

IF: 11.2

2007-01-01

Cancer Research

Abstract:2288 The marine ecosystem represents most of the species on the earth, and marine organisms provide numerous sources to develop novel compounds with multiple pharmacological potentials, including antiviral, antibacterial, anti-inflammatory, and anticancer and so on. The analgesic Conotoxin MVIIA (Prialt®) represents the first marine natural product drug to be introduced to the market. A number of marine compounds are currently in various phases of human clinical trials to treat different cancers, such as ecteinascidin, squalamine, aplidin, bryostatin-1, dolastatin-10 and ILX651. In this study, we screened thirty new marine sponge compounds to investigate their anticancer effects and inhibition of the activity of P-glycoprotein (P-gp, ABCB1) to reverse multidrug resistance (MDR) in human cancer cells. When these compounds were tested in two human drug-selected MDR cell lines KB-C2 and KB-V1, we found that one of the sipholane triterpenes, sipholenol A, in a concentration-dependent manner potentiated the cytotoxicity of several anticancer drugs including colchicine, vinblastine, and paclitaxel and significantly reversed the resistance of MDR cancer cells. Furthermore, sipholenol A had no effect on the response to cytotoxic agents in cells lacking P-gp expression or expressing other MDR-linked transporters including MRP1 (ABCC1) or breast cancer resistance protein (BCRP, ABCG2), and was not cytotoxic by itself at 50 μM, regardless of P-gp status. Accumulation and efflux studies with the P-gp substrate [ 3 H]-paclitaxel demonstrated that sipholenol A time-dependently increased the intracellular accumulation of [ 3 H]-paclitaxel by directly inhibiting P-gp-mediated drug efflux. In addition, sipholenol A did not have any effect on the expression of P-gp after treating MDR cancer cells for seventy-two hours, however, it did inhibit the photolabeling of P-gp with [ 125 I]- Iodoarylazidoprazosin. We conclude that sipholenol A interacts directly with P-gp and sipholane triterpenes are a new class of potential reversing agents for treatment of MDR in P-gp overexpressing tumors.